Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044564 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
A Phase 2 study of Carcinoma, Renal Cell, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 20
- Study locations
NCT00044564: Completed Phase 2 study of Carcinoma, Renal Cell, sponsored by Bayer.
NCT00044564 is a Phase 2 study of Carcinoma, Renal Cell that has completed, run by Bayer. The registered enrollment target is 54 participants, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00044564, a Phase 2 study of Carcinoma, Renal Cell, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 20
- Study locations
Study Summary
In patients with renal cell cancer, most frequent methods of treatment include surgery, chemotherapy, hormonal therapy, and immunotherapy. Renal cell carcinoma is usually considered to be radioresistant and chemoresistant. In patients with metastatic disease, the options are limited. The taxanes are among the most commonly used class of chemotherapy agents in clinical oncology today but they are not effective in renal cancers; the development of Bay 59-8862 targets taxane-resistant tumors and the current protocol is designed to test the safety and efficacy of Bay 59-8862 in patients with advanced renal cell carcinoma.
Conditions Studied
Interventions
- DRUG Bay 59-8862
Study Locations (20)
Maryland
- - Baltimore
- - Greenbelt
Michigan
- - Detroit
- - Southfield
Missouri
- - St Louis
- - St Louis
Alberta
- - Calgary
- - Edmonton
Other
- - Caen
- - Montpellier
Baden-Wurttemberg
- - Heidelberg
- - Tübingen
California
- - La Jolla
Indiana
- - Muncie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2001-12 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
What the finished NCT00044564 record still lists
NCT00044564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which Bay 59-8862 is the first listed.
NCT00044564 names 20 study sites across 14 states, led by Maryland, Michigan, Missouri.
Frequently Asked Questions
What is clinical trial NCT00044564 about?
NCT00044564 is a clinical study titled "Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma". In patients with renal cell cancer, most frequent methods of treatment include surgery, chemotherapy, hormonal therapy, and immunotherapy. Renal cell carcinoma is usually considered to be radioresistant and chemoresistant. In patients with metastatic disease, the options are limited. The taxanes are...
What is the current status of trial NCT00044564?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2001-12. Estimated completion is 2003-01.
What conditions does trial NCT00044564 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell.
What interventions are being tested in trial NCT00044564?
The interventions under investigation include: Bay 59-8862 (DRUG).
Who is sponsoring clinical trial NCT00044564?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00044564 being conducted?
This trial has 20 study locations across California, Indiana, Louisiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00044564's enrollment target sits among peer trials
54 22nd of 34 higher than 13 of 34 other Carcinoma, Renal Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Renal Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Dendritic Cell Vaccine in Kidney Cancer
RECRUITING · Phase 2
-
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
COMPLETED · Phase 2
-
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
COMPLETED · Phase 2
-
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
COMPLETED · Phase 2
-
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia